To data, there have been 13 reported injuries. Becton Dickinson (BD)/Carefusion 303 is recalling the Alaris infusion pump due to incompatibility issues with Cardinal Health Monoject syringes. The Food ...

The U.S. FDA said that BD (NYSE:BDX) has expanded its Class I voluntary recall to inform customers about the worst-case performance of the BD Alaris Pump Module model 8100 when used with certain ...

The Food and Drug Administration has posted a Class I notice about Becton Dickinson infusion pumps affected by compatibility issues with Cardinal Health Monoject syringes. Cardinal sent an urgent ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. BD has expanded a Class I Alaris recall to cover 15 ...

A new group of recalls for a repair piece installed in some of BD’s Alaris infusion pumps joins more than a dozen others on the long list of serious recalls involving the device in the last decade.

FDA has assigned a Class I designation to a recall of CareFusion Alaris infusion pumps, originally announced last month. The agency gave the same designation to a recall of frame membranes that Elite ...

FRANKLIN LAKES, N.J., July 18, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided an update on two voluntary recalls ...

CareFusion is recalling 7,418 units of its Alaris Syringe infusion pump, a corrective action that the FDA just deemed Class 1. This marks CareFusion's ninth Class 1 recall of an Alaris device since ...

The FDA has identified this as a Class I recall, the most serious type of recall. There have been 13 reported injuries. There have been no reports of death. Get the Strategy to Trade Pre-Fed Setups ...